GlassScriptPhysician profile
Bradley A Appl
NPI 1770559494
$6,800.14
in general payments reported to CMS, 2019-2025
52 companies · $1,491 in 2025
The $1,491 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,077 · 2020: $306 · 2021: $822 · 2022: $733 · 2023: $818 · 2024: $1,552 · 2025: $1,491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,836 · Education: $25.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,835.76 |
| Education | $25.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $802.39 | 2020-2025 | Vraylar, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $652.03 | 2019-2025 | |
| Lilly USA, LLC | $568.46 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $445.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $336.00 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $327.43 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Axsome Therapeutics, INC. | $312.62 | 2023-2025 | Auvelity |
| Amgen INC. | $249.38 | 2019-2025 | Repatha, Otezla, Otezla |
| Otsuka America Pharmaceutical, INC. | $226.85 | 2021-2025 | Rexulti, Nuedexta |
| Astellas Pharma US INC | $219.34 | 2019 | |
| Medline Industries LP | $191.72 | 2024-2025 | |
| Mannkind Corporation | $189.83 | 2019-2020 | |
| Lundbeck LLC | $184.43 | 2021-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $153.53 | 2019-2024 | Airsupra, Fasenra |
| Sunovion Pharmaceuticals INC. | $144.36 | 2019-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Appl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.